4/24
08:00 am
calc
CalciMedica Announces Last Patient Enrolled in Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis
High
Report
CalciMedica Announces Last Patient Enrolled in Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis
4/1
10:15 am
calc
CalciMedica, Inc. (NASDAQ: CALC) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $14.00 price target on the stock.
Medium
Report
CalciMedica, Inc. (NASDAQ: CALC) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $14.00 price target on the stock.
4/1
08:09 am
calc
CalciMedica, Inc. (NASDAQ: CALC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
High
Report
CalciMedica, Inc. (NASDAQ: CALC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
3/28
07:09 am
calc
CalciMedica Reports 2023 Financial Results and Provides Clinical & Corporate Updates [Yahoo! Finance]
Low
Report
CalciMedica Reports 2023 Financial Results and Provides Clinical & Corporate Updates [Yahoo! Finance]
3/28
07:00 am
calc
CalciMedica Reports 2023 Financial Results and Provides Clinical & Corporate Updates
Low
Report
CalciMedica Reports 2023 Financial Results and Provides Clinical & Corporate Updates
3/18
03:11 pm
calc
CalciMedica, Inc. (NASDAQ: CALC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Low
Report
CalciMedica, Inc. (NASDAQ: CALC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
3/13
08:00 am
calc
CalciMedica Presents Data from Preclinical Studies of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT Conference
Medium
Report
CalciMedica Presents Data from Preclinical Studies of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT Conference
2/28
06:57 pm
calc
CalciMedica Announces Presentation of Data from a Preclinical Study of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT Conference
Low
Report
CalciMedica Announces Presentation of Data from a Preclinical Study of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT Conference
2/16
08:10 am
calc
CalciMedica, Inc. (NASDAQ: CALC) is now covered by analysts at Jonestrading. They set a "buy" rating and a $22.00 price target on the stock.
Medium
Report
CalciMedica, Inc. (NASDAQ: CALC) is now covered by analysts at Jonestrading. They set a "buy" rating and a $22.00 price target on the stock.
2/13
01:18 pm
calc
CalciMedica, Inc. (NASDAQ: CALC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Low
Report
CalciMedica, Inc. (NASDAQ: CALC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
2/13
08:00 am
calc
CalciMedica Announces FDA Clearance of IND Application for Phase 2 Trial of Auxora™ for the Treatment of Severe Acute Kidney Injury
High
Report
CalciMedica Announces FDA Clearance of IND Application for Phase 2 Trial of Auxora™ for the Treatment of Severe Acute Kidney Injury
2/7
04:05 pm
calc
CalciMedica to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Medium
Report
CalciMedica to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
1/29
08:12 am
calc
CalciMedica, Inc. (NASDAQ: CALC) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $20.00 price target on the stock.
High
Report
CalciMedica, Inc. (NASDAQ: CALC) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $20.00 price target on the stock.